Canadian Team Validates Spartan's Point-of-Care CYP2C19 Test to Personalize Anti-Platelet Treatment
November 30, 2011
Canadian Team Validates Spartan's Point-of-Care CYP2C19 Test to Personalize Anti-Platelet Treatment
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- Study Finds Genomic/Clinical Combo to Be Best Predictor of Complications in Stent Patients on Plavix
November 2, 2011 / Pharmacogenomics Reporter - Spartan Bioscience Building Evidence for Point-of-Care PGx Testing to Guide Antiplatelet Therapy
March 13, 2013 / Pharmacogenomics Reporter - CollabRx Expands Treatment Guidance to Lung Cancer, Partners with CAP for Patient Outreach
February 29, 2012 / Pharmacogenomics Reporter - Genome BC Funds $9.8M Project to Identify Subgroups in Medulloblastoma for Personalized Treatment
February 15, 2012 / Pharmacogenomics Reporter - Researchers ID Molecular Subtypes of Gastric Cancer Predictive of Survival and Drug Response
August 3, 2011 / Pharmacogenomics Reporter